A NEW breast cancer treatment, trialled at Queen Alexandra Hospital in Cosham, will not be routinely available in England.
NHS watchdog the National Institute for Health and Care Excellence (Nice) has criticised makers of the treatment, known as Kadcyla, for the cost of the drug, which is £90,000 per patient.
The treatment helps deal with an advanced and aggressive type of breast cancer called advanced HER2-positive and it can help prolong life by six months to a year.
But Nice has rejected the drug for NHS use despite pharmaceutical company Roche ‘significantly’ lowering the price to an undisclosed figure.
Dr Jayson Dallas, general manager of Roche Products Limited, said: ‘Despite Roche offering a significant discount, we are once again disappointed that Nice has not shown any flexibility on access to Kadcyla.’
But Nice chief executive Sir Andrew Dillon, said: ‘Although Roche proposed a discount to the full list price of Kadcyla, it made little difference to its value for money, leaving it well above the top of our specially extended range of cost effectiveness for cancer drugs.’